Key facts
- Deepcell’s last known valuation is $223.0M (Mar 2022).
- It has raised $98.0M across 3 recorded rounds; the latest was Later Stage VC ($73.0M) in Jan 2022.
- Notable investors include Andreessen Horowitz, DCVC, Jeff Dean, Fifty Years, Horizons Ventures — 11 tracked in total.
- Deepcell has filed 3 Form Ds with the SEC since 2017, most recently Oct 2022 ($73.0M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Deepcell
Funding rounds
3 roundsAbout Deepcell
Developer of microfluidic imaging platform designed to offer non-invasive genetic tests with diagnostic-level accuracy. The company's platform utilizes artificial intelligence to classify cells based on detailed visual features and isolates viable cells based on morphological distinctions, enabling researchers to eliminate the need for invasive diagnostic tests.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2015
- Employees
- 100
- Website
- deepcell.com/
- Ownership
- Privately Held (backing)
Deepcell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deepcell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deepcell in its N-PORT filings yet. We sweep new filings monthly.